The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis
- 28 October 2010
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 10 (12), 1743-1752
- https://doi.org/10.1517/14712598.2010.532785
Abstract
Systemic juvenile idiopathic arthritis (sJIA) is a debilitating childhood disease presenting with fever, rash and arthritis. Current therapy consisting mainly of corticosteroids, NSAIDs and methotrexate, can be inefficient and is often accompanied by many serious adverse events. Although an IL-1 receptor antagonist (anakinra) seems to be very efficient in case series, it is not registered for use in sJIA. Pediatric rheumatologists all over the world are having a hard time to convince insurance companies to approve off-label use of this drug for their sJIA patients. Using the MeSH terms 'Arthritis Juvenile Rheumatoid' and 'Interleukin 1 Receptor Antagonist Protein', we searched MEDLINE, EMBASE and reference lists of selected articles. This review is largely based on manuscripts from 2005 to 2010 and abstracts presented at the major (pediatric) rheumatology congresses. This review summarizes the data of 140 children with sJIA treated with anakinra and enables an understanding in the benefit-risk profile of anakinra in sJIA patients. Anakinra has shown to be a very efficient and quick acting medicine in reducing symptoms even in therapy-resistant sJIA patients with typically poor outcomes.Keywords
This publication has 37 references indexed in Scilit:
- Adult Outcomes of Patients with Juvenile Idiopathic ArthritisHormone Research in Paediatrics, 2009
- The pattern of response to anti–interleukin‐1 treatment distinguishes two subsets of patients with systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2008
- Juvenile idiopathic arthritisThe Lancet, 2007
- Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritisCurrent Opinion in Rheumatology, 2005
- Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritisThe Journal of Pediatrics, 2005
- Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockadeThe Journal of Experimental Medicine, 2005
- The German etanercept registry for treatment of juvenile idiopathic arthritisAnnals Of The Rheumatic Diseases, 2004
- Burden and cost of illness in patients with juvenile idiopathic arthritisAnnals Of The Rheumatic Diseases, 2004
- Natural killer cell dysfunction: A common pathway in systemic‐onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?Arthritis & Rheumatism, 2004
- Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort studyArthritis & Rheumatism, 2000